Calcitonin Salmon Suppliers & Bulk Manufacturers
Available Forms: Injection / nasal spray
Available Strengths: 100 IU/mL, 200 IU/mL
Reference Brands: Fortical (USA), Miacalcin (USA)
Category:
Osteoporosis
Calcitonin salmon is available in Injection / nasal spray
and strengths such as 100 IU/mL, 200 IU/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Calcitonin salmon is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Calcitonin salmon can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Calcitonin salmon, also known as salmon calcitonin, is a synthetic polypeptide hormone used in the management of disorders related to bone metabolism and calcium regulation. It is a derivative of human calcitonin and consists of 32 amino acids. Due to its higher potency and longer duration of action compared to human calcitonin, salmon calcitonin has become the preferred form for clinical use. It is primarily indicated for the treatment of postmenopausal osteoporosis, Paget’s disease of bone, and hypercalcemia.
Calcitonin salmon is available as an injectable formulation for intravenous, intramuscular, or subcutaneous administration, as well as a noninvasive intranasal spray. The nasal spray formulation received early regulatory approval for osteoporosis treatment and offers an alternative for patients who prefer non-injectable therapy, although its bioavailability is lower compared to injectable forms. In addition, oral formulations of salmon calcitonin are under clinical development, with advanced candidates having reached late-stage clinical trials.
The therapeutic action of calcitonin salmon is mediated through inhibition of osteoclast activity, resulting in reduced bone resorption and increased renal excretion of calcium. These effects lead to decreased serum calcium levels and stabilization of bone mass, making calcitonin salmon beneficial in managing bone and calcium-related disorders.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing